STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #421 by analyst upside · 2026-06-27
IBIO
iBio, Inc.
Healthcare · Market Cap $83M · P/E 0x
ANALYST PRICE TARGET
+230.8%
implied upside to consensus target
Current Price $1.67
Consensus Target $5.53
Bull Target $7.0
Bear Target $4.2
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
8
Hold
0
Sell
0
52-Week Low $0.56
52-Week High $3.82
YTD Return -17.3%
FUNDAMENTALS
Market Cap $83M
P/E Ratio (TTM) N/A
Forward P/E -5.4x
EPS (TTM) $-0.56
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.56
52-Week High $3.82
Current Price $1.67
Bear Target $4.2
Bull Target $7.0
● Now $1.67 ● Target $5.53
TRADING DATA
Avg Volume 853K
YTD Return -17.3%
Analyst Count 8
Consensus Buy
Upside to Target +230.8%
Last Updated 2026-06-27

ANALYST SUMMARY

iBio, Inc. (IBIO) is currently trading at $1.67 with a Wall Street consensus price target of $5.53, implying potential upside of 230.8% over the next 12 months. 8 analysts currently cover IBIO, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $7.0, while the most cautious has a target of $4.2.

IBIO operates in the Healthcare sector with a market capitalisation of $83M. The stock is down 17.3% year-to-date and is currently trading near the lower end of its 52-week range of $0.56 – $3.82.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IBIO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Raymond James ● Initiated
Outperform 2026-06-08 Building track record
Chardan Capital — Reiterated
Buy → Buy 2026-04-09 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-03-18 33% win rate (6 calls)
Jones Trading ● Initiated
Buy 2026-03-03 57% win rate (14 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-02-12 33% win rate (6 calls)
Oppenheimer ● Initiated
Outperform 2025-10-21 14% win rate (7 calls)
Leerink Partners ● Initiated
Outperform 2025-10-17 29% win rate (7 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-06-25 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →